» Articles » PMID: 35386945

NT-proBNP, Hs-cTnT, and CRP Predict the Risk of Cardiopulmonary Outcomes in Systemic Sclerosis: Findings from the Canadian Scleroderma Research Group

Overview
Date 2022 Apr 7
PMID 35386945
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The aim of this study was to determine the independent value of N-terminal pro b-type natriuretic peptide, high-sensitivity cardiac troponin T, and C-reactive protein to predict onset of cardiopulmonary disease in a large, multi-center systemic sclerosis cohort followed prospectively.

Methods: Subjects from the Canadian Scleroderma Research Group registry with data on N-terminal pro b-type natriuretic peptide, high-sensitivity cardiac troponin T, and C-reactive protein were identified. Outcomes of interest were death, systolic dysfunction (left ventricular ejection fraction < 50% or medications for heart failure), pulmonary arterial hypertension by right heart catheterization, pulmonary hypertension by cardiac echocardiography (systolic pulmonary artery pressures ⩾ 45 mmHg), arrhythmias (pacemaker/implantable cardiac defibrillator or anti-arrhythmic medications), and interstitial lung disease. Multivariate Cox proportional hazard models were generated for each outcome.

Results: A total of 675 subjects were included with a mean follow-up of 3.0 ± 1.8 years. Subjects were predominantly women (88.4%) with mean age of 58.2 ± 11.3 years and mean disease duration of 13.7 ± 9.1 years. One hundred and one (101, 15%) subjects died during follow-up, 37 (6.4 %) developed systolic dysfunction, 18 (2.9%) arrhythmias, 34 (5.1%) pulmonary arterial hypertension, 43 (7.3%) pulmonary hypertension, and 48 (12.3%) interstitial lung disease. In multivariate analyses, elevated levels of N-terminal pro b-type natriuretic peptide, high-sensitivity cardiac troponin T, and C-reactive protein were associated with increased risk of death, while elevated levels of N-terminal pro b-type natriuretic peptide and C-reactive protein were associated with increased risk of developing pulmonary hypertension.

Conclusion: In systemic sclerosis, N-terminal pro b-type natriuretic peptide, high-sensitivity cardiac troponin T, and C-reactive protein have independent predictive value for death and pulmonary hypertension. A larger study would be required to determine the predictive value of these biomarkers for less common systemic sclerosis outcomes.

Citing Articles

Multimodal Screening for Pulmonary Arterial Hypertension in Systemic Scleroderma: Current Methods and Future Directions.

Dragoi I, Rezus C, Burlui A, Bratoiu I, Rezus E Medicina (Kaunas). 2025; 61(1).

PMID: 39859001 PMC: 11766816. DOI: 10.3390/medicina61010019.


The relationship between serum levels of LOX-1, hs-cTnT, NGAL, and renal function, and their diagnostic value in patients with chronic kidney disease: a retrospective study.

Chai L, Zeng J, Gong L, Li Z, Wang F, Liu Z BMC Nephrol. 2024; 25(1):427.

PMID: 39604892 PMC: 11600683. DOI: 10.1186/s12882-024-03875-6.


Chronic low-grade inflammation in patients with systemic sclerosis is associated with increased risk for arteriosclerotic cardiovascular disease.

Heilmeier U, Feldmann D, Leynes A, Seng M, Jandova I, Keute M Front Med (Lausanne). 2024; 11:1446268.

PMID: 39564499 PMC: 11573558. DOI: 10.3389/fmed.2024.1446268.


Progression, Management, and Outcome of Aortic Valve Stenosis in Systemic Sclerosis: A Case Series.

Vergara A, Orlando A, Caiazza E, Vettori S, Cuomo G, Argiento P J Cardiovasc Dev Dis. 2024; 11(9).

PMID: 39330332 PMC: 11432032. DOI: 10.3390/jcdd11090274.


Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review.

Bazso A, Szodoray P, Shoenfeld Y, Kiss E Clin Rheumatol. 2024; 43(10):3055-3072.

PMID: 39210206 PMC: 11442557. DOI: 10.1007/s10067-024-07123-y.


References
1.
Fisher M, Forfia P, Chamera E, Housten-Harris T, Champion H, Girgis R . Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179(7):615-21. PMC: 2720125. DOI: 10.1164/rccm.200811-1691OC. View

2.
Champion H . The heart in scleroderma. Rheum Dis Clin North Am. 2008; 34(1):181-90. PMC: 2361099. DOI: 10.1016/j.rdc.2007.12.002. View

3.
Tyndall A, Bannert B, Vonk M, Airo P, Cozzi F, Carreira P . Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69(10):1809-15. DOI: 10.1136/ard.2009.114264. View

4.
Komocsi A, Vorobcsuk A, Faludi R, Pinter T, Lenkey Z, Kolto G . The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford). 2012; 51(6):1027-36. DOI: 10.1093/rheumatology/ker357. View

5.
Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J . Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken). 2012; 64(9):1405-14. DOI: 10.1002/acr.21716. View